Status:
COMPLETED
Acceptability of a Fixed Combination of Fenofibrate and Metformin
Lead Sponsor:
Solvay Pharmaceuticals
Conditions:
Dyslipidemia/Glucose Metabolism Disorder
Eligibility:
All Genders
20-80 years
Phase:
PHASE3
Brief Summary
The primary objective was to assess the acceptability of a 4-week treatment of 4 new fixed-dose combinations of fenofibrate and metformin, in patients with type 2 diabetes and dyslipidemia.
Eligibility Criteria
Inclusion
- Patients with type 2 diabetes mellitus and dyslipidemia.
Exclusion
- Type 1 diabetes, uncontrolled type 2 diabetes, - HbA1c ≥ 10 % - Fasting plasma glucose \> 300 mg/dL - Triglycerides \> 500 mg/dL
Key Trial Info
Start Date :
April 1 2005
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
69 Patients enrolled
Trial Details
Trial ID
NCT00348725
Start Date
April 1 2005
Last Update
September 3 2007
Active Locations (25)
Enter a location and click search to find clinical trials sorted by distance.
1
Site 24
Anzin, France
2
Site 23
Bachant, France
3
Site 21
Bauné, France
4
Site 32
Bersée, France